DHFR


Also found in: Medical.
AcronymDefinition
DHFRDiHydroFolate Reductase
DHFRDirac-Hartree-Fock-Roothaan
DHFRDrustvo Hrvatskih Filmskih Redatelja (Croatian: Croatian Society of Film Directors)
References in periodicals archive ?
5] Human genes: SLA, Src-like-adaptor; LST1, leukocyte-specific transcript 1; BENE, BENE protein; KRT24, keratin 24; C9orf3, chromosome 9 open reading frame 3; KIAA0779, KIAA0779 protein; TMCC1, transmembrane and coiledcoil domain family 1; ZNF292, zinc finger protein 292; LOC153222, adult retina protein; CBEP4, cytoplasmic polyadenylation element binding protein4; TICD2, tigger transposable element derived 2; UBAP2, ubiquitin associated protein 2; AVPI1, arginine vasopressin-induced 1; KIAA0669, the same as TSC22D2; TSC22D2, TSC22 domain family, member 2; DHFR, dihydrofolate reductase; MTR, 5-methoyltetrahydrofolate-homocysteine methyltransferase; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide; KA36, type I hair keratin; KRT4, Keratin 4; KRT9, Keratin 9.
Multiple copies of the DHFR gene havebeen found in tumor cells of some methotrexate-resistant patients, enabling the production of above-normal amounts of DHFR.
QM/MM and Inverse Design for Novel Therapeutics Targeting Drug-Resistant pfDHFR-TS Malaria Shows how QM/MM calculations with the Inverse Design algorithm are used to develop mutation-resistance inhibitors, by designing ligands that are active against 3 known mutations from DHFR from Plasmodium falciparum (malaria).
Similarly specific point mutations in the DHFR gene are also known to be associated with pyremethamine resistance: alanine to valine at 16, asparagine to isoleucine at 51, cysteine to asparagine at 59, serine to asparagine or threonine at 108 and isoleucine to leucine at 164.
Because the DHFR enzymatic assay may lack specificity and the radiochemical assay is time-consuming, there is a need for a more rapid and specific method that could be routinely applied to clinical practice.
The Company believes these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that pralatrexate may have a favorable safety and efficacy profile relative to methotrexate and other related DHFR inhibitors.
Through a discretionary allocation of 1 million core-hours at the Argonne Leadership Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will use Mira, a 10-petaflops IBM Blue Gene/Q supercomputer to investigate inhibitors of the dihydrofolate reductase enzyme, or DHFR, from multiple sources.
The DHFR enzyme inhibition assay is a sensitive and specific method for determining MTX concentrations in biological fluids, but current assay methods are labor-intensive and time-consuming.
The Company believes these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and other related DHFR inhibitors.
Pralatrexate is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes.